Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN2COVID: Inhaled Interferon α2b for COVID-19
NCT04988217Phase 2Completed
- Sponsor
- Pontificia Universidad Católica de Chile
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of interferon alfa-2b in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Pontificia Universidad Católica de Chile. Primary endpoints: Treatment-emergent adverse events at Day 11 and EuroQol Visual Analogue Scale at Day 5. Started Sep 2021; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04988217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988217.